Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 4 Multiple regression analysis of QoL at the three time periods (S1, S2, and S3)

Characteristic		Global health status			Physical functioning			Role functioning			Emotional functioning			Cognitive functioning			Social functioning
		S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3	S1	S2	S3
Agea		-0.04	-0.09	-0.2	0.12	0.12	0.05	0.44	-0.11	0.36	-0.06	-0.401	-0.06	-0.22	0.1	-0.04	0.15	0.33	0.23
Sexa		-3.42	3.04	-0.9	-1.51	0.03	-0.02	-8.47	4.16	-7.64	2.26	3.28	2.86	-3.84	2.48	3.1	1.91	3.41	-0.02
ECOGa		11.48	-3.84	6.95	21.491	8.54	15.71	14.12	-15.01	29.631	4.44	-6.42	-7.51	12.7636	6.65	-16.7	-15.26	-17.76	-13.8
HBVa		1.14	-2.14	-7.53	-7.03	-11.47	-9.52	-2.91	-9.5	-2.33	0.34	-8.79	-5.72	5.04	-11.76	-12.04	4.86	-2.02	-8.07
Previous systemic chemotherapya		7.88	4.22	5.17	5.12	0.63	-0.89	9.32	-0.47	2.49	3.04	-6.04	-5.53	-0.57	-2.98	-3.83	6.84	-1.42	-0.12
Surgical methoda		-4.57	-0.44	0.86	-2.74	0.36	8.32	7.11	8.92	-4.39	9.93	10.61	11.54	-7.77	17.232	16.781	33.222	16.73	2.54
HIPEC regimena		0.65	1.41	6.69	-0.93	-7.51	-6.67	-3.94	-4.08	4.79	-2.55	-0.21	-0.23	-0.85	-2.09	-5.98	-1.76	6.71	-0.76
MDASI-T
	SSa	-0.451	-0.07	-0.542	-0.21	-0.15	-0.01	-0.17	-0.15	0.18	-0.1	-0.41	-0.11	-0.682	0.07	-0.521	0.23	0.06	0.10
	DILa	-0.751	-0.711	-0.64	-0.44	-1.081	-1.372	-0.78	-1.393	-2.113	-0.611	-0.651	-1.493	-0.32	-0.461	-0.781	-1.483	-1.042	-1.893
Adjusted R2		0.4	0.28	0.63	0.35	0.47	0.55	0.32	0.41	0.58	0.27	0.4	0.58	0.37	0.32	0.64	0.45	0.37	0.65

^aβ coefficients;

¹P < 0.05;

²P < 0.01;

³P < 0.001.

DIL: Degree of interference with life; ECOG: Eastern Cooperative Oncology Group performance status; HBV: Hepatitis B; SS: Symptom severity; MDASI-T: MD Anderson Symptom Inventory-Taiwan version. S1: The first visit before CRS/HIPEC; S2: The second visit, the first outpatient follow-up visit after CRS/HIPEC; S3: The third visit, the outpatient visit 3 mo after CRS/HIPEC.